EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates

Daniel Thoresen iD, Kenta Matsuda iD, Akane Urakami, Mya Myat Ngwe Tun, Takushi Nomura, Meng Ling Moi, Yuri Watanabe, Momoko Ishikawa, Trang Thi Thu Hau, Hiroyuki Yamamoto, Yuriko Suzaki, Yasushi Ami und 4 weitere

Journal of Virology · 2024

DOI: 10.1128/jvi.00239-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Daniel Thoresen und 15 weiteren Autor:innen. Beteiligte Einrichtung: VLP Therapeutics, Inc., Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, Dengue, Dengue Vaccines. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Health Innovative Technology Fund (GHIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue virus (DENV) represents a significant global health burden, with 50% of the world’s population at risk of infection, and there is an urgent need for next-generation vaccines. Virus-like particle (VLP)-based vaccines, which mimic the antigenic structure of the virus but lack the viral genome, are an attractive approach. Here, we describe a dengue VLP (DENVLP) vaccine which generates a neutralizing antibody response against all four DENV serotypes in 100% of immunized non-human primates for up to 1 year. Additionally, DENVLP vaccination produced no ADE response against any of four DENV serotypes in vitro . DENVLP vaccination reduces viral replication in a non-human primate challenge model. We also show that transfer of purified IgG from immunized monkeys into immunodeficient mice protects against subsequent lethal DENV challenge, indicating a humoral mechanism of protection. These results indicate that this DENVLP vaccine is immunogenic and can be considered for clinical evaluation. Immunization of non-human primates with a tetravalent DENVLP vaccine induces high levels of neutralizing antibodies and reduces the severity of infection for all four dengue serotypes. IMPORTANCE Dengue is a viral disease that infects nearly 400 million people worldwide and causes dengue hemorrhagic fever, which is responsible for 10,000 deaths each year. Currently, there is no therapeutic drug licensed to treat dengue infection, which makes the development of an effective vaccine essential. Virus-like particles (VLPs) are a safe and highly immunogenic platform that can be used in young children, immunocompromised individuals, as well as healthy adults. In this study, we describe the development of a dengue VLP vaccine and demonstrate that it induces a robust immune response against the dengue virus for over 1 year in monkeys. The immunity induced by this vaccine reduced live dengue infection in both murine and non-human primate models. These results indicate that our dengue VLP vaccine is a promising vaccine candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAntibodies, ViralDengueDengue VaccinesDengue VirusVaccines, Virus-Like ParticleAnimalsFemaleMiceDisease Models, AnimalImmunoglobulin GMacaca fascicularisMacaca mulattaSerogroupVaccinationVirus Replication

Stichwörter der Autor:innen

NHPVLPchallengedenguevaccine

Substanzen

Antibodies, NeutralizingAntibodies, ViralDengue VaccinesImmunoglobulin GVaccines, Virus-Like Particle

Autor:innen und Institutionen

  • VLP Therapeutics, Inc., Gaithersburg, Maryland, USA.
  • Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
  • Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
  • AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Department of Developmental Medical Sciences, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Daniel Thoresen, Kenta Matsuda, Wataru Akahata

Förderung

  • Global Health Innovative Technology Fund (GHIT)

Zitieren

APA

Thoresen, D., Matsuda, K., Urakami, A., Ngwe Tun, M. M., Nomura, T., Moi, M. L., Watanabe, Y., Ishikawa, M., Hau, T. T. T., Yamamoto, H., Suzaki, Y., Ami, Y., Smith, J. F., Matano, T., Morita, K., & Akahata, W. (2024). A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates. Journal of Virology. https://doi.org/10.1128/jvi.00239-24

Vancouver

Thoresen D, Matsuda K, Urakami A, Ngwe Tun MM, Nomura T, Moi ML, et al. A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates. Journal of Virology. 2024. doi:10.1128/jvi.00239-24

BibTeX
@article{Thoresen2024,
  author = {Thoresen, Daniel and Matsuda, Kenta and Urakami, Akane and Ngwe Tun, Mya Myat and Nomura, Takushi and Moi, Meng Ling and Watanabe, Yuri and Ishikawa, Momoko and Hau, Trang Thi Thu and Yamamoto, Hiroyuki and Suzaki, Yuriko and Ami, Yasushi and Smith, Jonathan F and Matano, Tetsuro and Morita, Kouichi and Akahata, Wataru},
  title = {A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.00239-24}
}
Kostenlos starten →